secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMGC Holdings Inc. (ELAB)
CIK:        0001840563
Form:       8-K
Filed at:   2026-09-02T21:04:24+00:00
Accession:  0001213900-26-096784
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMGC's NorthStrive expands AI drug program with Yuva, advances four compounds
-----------------------------------------------------------------------------

- NorthStrive (PMGC) and Yuva execute First Amendment launching three-phase Expansion Program for four AI-discovered compounds.
- Program builds on July 1, 2026 Phase III results (significant ANT1 increases); ~6 months to lead compound nomination.
- Amendment grants right of first refusal for exclusive cardiometabolic license beyond Cardiac Diseases and Obesity.
- Company increased authorized shares to 1.5B (1B common, 500M preferred) via Certificate of Amendment, 60.34% approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/0001213900-26-096784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/ea0304419-8k_pmgchold.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-096784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer